Sanofi Consumer Healthcare India reported a 21% year-on-year (YoY) increase in its Q2 profit, reaching ₹60.7 crore.
The company's revenue for the second quarter of 2025 grew by 28% to ₹220.9 crore, supported by successful product launches and export operations. Sales growth for the quarter was 27.5% from Q12025 and 27.6% year-on-year from 2024.
Himanshu Bakshi, Managing Director, said the results were driven by a "focused portfolio, research-led innovation, and an agile organization". He also highlighted the successful relaunch of two previously recalled products, the introduction of a new product, and the commencement of export operations.
The company's half-year financial highlights show a profit after tax of ₹110.7 crore and sales of products at ₹393.5 crore.
The company launched Allegra D, a new product in the allergy segment.
It also relaunched Depura 60k and Combiflam Suspension, which had been voluntarily recalled last year.
Legacy brands such as Avil and Depura continue to do well, the company said.
The company noted that the quarter and half-year financials are not directly comparable due to the demerger from Sanofi India Limited and the voluntary recall of certain product variants. The demerger became effective on June 1, 2024, and established Sanofi Consumer Healthcare India Limited as a separate legal entity.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
